Innate Pharma S.A (IPHA): Long-Term Debt to Capital Ratio

This daily price chart for Innate Pharma S.A. (IPHA) demonstrates the 0.00 indicator. Innate Pharma S.A. (IPHA) delegates the synthesis of complex compounds and the conduct of trials to external contractors, remaining a research hub. Business growth relies on the development of antibody and NK-cell technologies through alliances with industry behemoths. Meanwhile, its status as a French developer guarantees stable operations and access to US and European markets.

This ratio determines the company's dependence on borrowed capital with a maturity of over one year relative to the amount of equity. The trend of the long-term debt-to-equity ratio demonstrates the balance between financial stability and the use of leverage to scale the antibody and NK-cell platforms of Innate Pharma S.A. (IPHA) as part of its expansion strategy in the oncology market.